[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100464088":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":35,"locations":41,"responsibleParty":58,"collaborators":34,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":34,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":34,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":34,"overallStatus":44,"whyStopped":34,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Assiut University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group C","PLACEBO_COMPARATOR","Group C, will be received saline (loading dose of 1gm of saline 0.9%, followed by a 1gm of maintenance saline dose over 8 hours for 48 h).",[13],"Other: Saline",{"label":15,"type":16,"description":17,"interventionNames":18},"Group T","EXPERIMENTAL","Group T, will be received TXA (loading dose of 1gm of TXA, followed by a 1gm of maintenance dose over 8 hours for 48 h).",[19],"Drug: Tranexamic acid",[21,27],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"Saline","Giving saline (loading dose of 1gm of saline 0.9%, followed by a 1gm of maintenance saline dose over 8 hours for 48 h).",[9],[26],"Normal saline",{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"DRUG","Tranexamic acid","Giving TXA (loading dose of 1gm of TXA, followed by a 1gm of maintenance dose over 8 hours for 48 h).",[15],[33],"Cyclokapron",null,[36],{"name":37,"role":38,"phone":39,"phoneExt":34,"email":40},"Omar Soliman","CONTACT","01101266040","omar@aun.edu.eg",[42],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Assiut university hospital","RECRUITING","Asyut","Assuit","Assuit universi","Egypt","EG",{"type":51,"coordinates":52},"Point",[53,54],31.18368,27.18096,{"lat":54,"lon":53},[57],{"name":37,"role":38,"phone":34,"phoneExt":34,"email":40},{"type":59,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":34,"oldOrganization":34},"PRINCIPAL_INVESTIGATOR","Omar Makram Soliman","Lecturer of anesthesia and ICU","100464088","phase-3-tranexamic-acid-in-traumatic-brain-injury-100464088",false,"NCT05323149","Tranexamic Acid in Traumatic Brain Injury","The Impact of Early Use of Tranexamic Acid in Traumatic Brain Injury Upon the Inflammatory Response and Outcome","Inclusion Criteria:\n\n* Isolated traumatic brain injury patients (mild or moderate cases)\n* GCS \\> 8\n* non penetrating TBI in 8 hours onset\n* Age ≥ 18 years\n\nExclusion Criteria:\n\n* Patient in cardiac arrest\n* Patients with coagulopathies\n* Renal failure patients\n* pregnancy\n* Patient refusal to participate","ALL","18 Years","65 Years",{"count":73,"type":74},60,"ESTIMATED","INTERVENTIONAL",[77],"PHASE3","In this study, our aim is to investigate the role of tranexamic acid for modulating the inflammation in patients with traumatic brain injury (TBI).",[80],"Inflammatory Response","2025-12-27",{"date":83,"type":84},"2026-01-02","ACTUAL",{"date":86,"type":84},"2022-05-18",{"date":88,"type":74},"2027-10-15",{"name":5,"class":6},1]